JP2018522880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522880A5 JP2018522880A5 JP2017568234A JP2017568234A JP2018522880A5 JP 2018522880 A5 JP2018522880 A5 JP 2018522880A5 JP 2017568234 A JP2017568234 A JP 2017568234A JP 2017568234 A JP2017568234 A JP 2017568234A JP 2018522880 A5 JP2018522880 A5 JP 2018522880A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- dengue virus
- denv
- composition according
- pfu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021113634A JP2021176862A (ja) | 2015-07-02 | 2021-07-08 | デングウイルス及び樹状細胞による併用療法のための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562231351P | 2015-07-02 | 2015-07-02 | |
| US62/231,351 | 2015-07-02 | ||
| PCT/US2016/040787 WO2017004567A1 (en) | 2015-07-02 | 2016-07-01 | Compositions and methods for combination therapy with dengue virus and dendritic cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021113634A Division JP2021176862A (ja) | 2015-07-02 | 2021-07-08 | デングウイルス及び樹状細胞による併用療法のための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522880A JP2018522880A (ja) | 2018-08-16 |
| JP2018522880A5 true JP2018522880A5 (OSRAM) | 2019-08-08 |
Family
ID=57609586
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568234A Pending JP2018522880A (ja) | 2015-07-02 | 2016-07-01 | デングウイルス及び樹状細胞による併用療法のための組成物及び方法 |
| JP2021113634A Pending JP2021176862A (ja) | 2015-07-02 | 2021-07-08 | デングウイルス及び樹状細胞による併用療法のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021113634A Pending JP2021176862A (ja) | 2015-07-02 | 2021-07-08 | デングウイルス及び樹状細胞による併用療法のための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US9730989B2 (OSRAM) |
| EP (1) | EP3316897A4 (OSRAM) |
| JP (2) | JP2018522880A (OSRAM) |
| CN (1) | CN107921063A (OSRAM) |
| CA (1) | CA2991212A1 (OSRAM) |
| DE (1) | DE202016008300U1 (OSRAM) |
| MX (1) | MX2018000052A (OSRAM) |
| WO (1) | WO2017004567A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3316897A4 (en) | 2015-07-02 | 2019-03-13 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS |
| JP2018535191A (ja) * | 2015-09-26 | 2018-11-29 | プライムヴァックス イミュノ−オンコロジー，インク． | 樹状細胞を産生するための組成物及び方法 |
| JP2020500847A (ja) | 2016-11-16 | 2020-01-16 | プライムヴァックス イミュノ−オンコロジー，インク． | 癌の処置のための併用免疫療法 |
| CA3049225A1 (en) * | 2017-01-04 | 2018-07-12 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for therapy with dengue virus |
| CA3067164A1 (en) | 2017-06-12 | 2018-12-20 | Washington University | Zika virus strains for treatment of glioblastoma |
| MX2019015194A (es) * | 2017-06-15 | 2020-08-03 | Primevax Immuno Oncology Inc | Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas. |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1015972A (en) | 1905-09-25 | 1912-01-30 | Westinghouse Electric & Mfg Co | Electric switch. |
| US1035755A (en) | 1908-07-21 | 1912-08-13 | Glenn S Smith | Draftsman's apparatus. |
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| WO1999042564A2 (en) * | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| US6524587B1 (en) * | 1998-05-05 | 2003-02-25 | Bruce W. Lyday | Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors |
| US6048686A (en) * | 1998-05-05 | 2000-04-11 | Randy Kyle Brown | Hyperthermia and immunotherapy for cancer |
| US6511667B1 (en) * | 1999-03-26 | 2003-01-28 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-2 virus vaccine |
| DE60041250D1 (de) | 1999-03-26 | 2009-02-12 | Us Army | Multivalenter dengue-virus impfstoff |
| EP1168924A4 (en) | 1999-03-31 | 2002-09-04 | Univ Pittsburgh | DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL |
| EP1484064A1 (en) | 2003-06-04 | 2004-12-08 | Gesellschaft für Biotechnologische Forschung | Therapeutical composition containing dentritic cells and use thereof |
| CA2571849A1 (en) | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | Anticancer agent containing dendritic cell having rna virus transferred thereinto |
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| JP5020935B2 (ja) * | 2005-04-08 | 2012-09-05 | アルゴス セラピューティクス，インコーポレイティド | 樹状細胞組成物および方法 |
| EP2589602B1 (en) | 2006-08-15 | 2016-04-06 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Development of dengue virus vaccine components |
| WO2008039974A2 (en) * | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| WO2013188315A1 (en) * | 2012-06-10 | 2013-12-19 | Inviragen, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| CA2793458A1 (en) | 2010-03-15 | 2011-09-22 | The Trustees Of The University Of Pennsylvania | System and method of preparing and storing activated mature dendritic cells |
| PE20140646A1 (es) | 2011-05-26 | 2014-05-29 | Glaxosmithkline Biolog Sa | Vacuna de virus de dengue inactivado |
| EP2543386A1 (en) * | 2011-07-05 | 2013-01-09 | Sotio a.s. | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure |
| WO2013154778A1 (en) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| CA2939093A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| AU2016259020B2 (en) | 2015-05-07 | 2021-12-09 | Baylor College Of Medicine | Dendritic cell immunotherapy |
| EP3316897A4 (en) | 2015-07-02 | 2019-03-13 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS |
| JP2018535191A (ja) | 2015-09-26 | 2018-11-29 | プライムヴァックス イミュノ−オンコロジー，インク． | 樹状細胞を産生するための組成物及び方法 |
| JP2020500847A (ja) | 2016-11-16 | 2020-01-16 | プライムヴァックス イミュノ−オンコロジー，インク． | 癌の処置のための併用免疫療法 |
| CA3049225A1 (en) | 2017-01-04 | 2018-07-12 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for therapy with dengue virus |
| MX2019015194A (es) | 2017-06-15 | 2020-08-03 | Primevax Immuno Oncology Inc | Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas. |
-
2016
- 2016-07-01 EP EP16818917.3A patent/EP3316897A4/en not_active Withdrawn
- 2016-07-01 WO PCT/US2016/040787 patent/WO2017004567A1/en not_active Ceased
- 2016-07-01 CA CA2991212A patent/CA2991212A1/en not_active Abandoned
- 2016-07-01 DE DE202016008300.8U patent/DE202016008300U1/de not_active Expired - Lifetime
- 2016-07-01 US US15/200,751 patent/US9730989B2/en not_active Expired - Fee Related
- 2016-07-01 CN CN201680050897.6A patent/CN107921063A/zh active Pending
- 2016-07-01 MX MX2018000052A patent/MX2018000052A/es unknown
- 2016-07-01 JP JP2017568234A patent/JP2018522880A/ja active Pending
-
2017
- 2017-06-30 US US15/639,632 patent/US9849167B2/en active Active
- 2017-10-31 US US15/799,793 patent/US10159727B2/en active Active
-
2018
- 2018-10-26 US US16/172,487 patent/US10357553B2/en not_active Expired - Fee Related
-
2019
- 2019-04-19 US US16/389,445 patent/US10946080B2/en not_active Expired - Fee Related
-
2021
- 2021-02-02 US US17/165,270 patent/US20210187086A1/en not_active Abandoned
- 2021-07-08 JP JP2021113634A patent/JP2021176862A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522880A5 (OSRAM) | ||
| JP2016531927A5 (OSRAM) | ||
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| WO2015193359A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| MX2016014711A (es) | Inmunoterapia novedosa contra varios tumores de la sangre, con la leucemia mielogena aguda (lma). | |
| WO2015013461A3 (en) | Cancer vaccination with antigen evolution | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| GB0700058D0 (en) | Anti-tumor vaccine based on normal cells | |
| NZ711946A (en) | Newcastle disease viruses and uses thereof | |
| MX379423B (es) | Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales. | |
| MX376066B (es) | Anticuerpos dirigidos contra cd127. | |
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| BR112013031084A2 (pt) | meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas | |
| WO2018083220A3 (en) | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines | |
| EP2574170A4 (en) | IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS | |
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
| WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
| CN104245736A (zh) | 抗人死亡受体5胞外区的人源化单克隆抗体 | |
| EA201790223A1 (ru) | Водный препарат, содержащий парацетамол и ибупрофен | |
| MX2021003826A (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. | |
| CY1115803T1 (el) | Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα | |
| WO2017041092A3 (en) | Anti-survivin antibodies for cancer therapy | |
| EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| WO2020023776A3 (en) | Compositions and methods for inhibiting cancers and viruses |